A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia

Ohnishi, Kazunori; Tomonaga, Masao; Kamada, Nanao; Onozawa, Kimio; Kuramoto, Atsushi; Dohy, Hiroo; Mizoguchi, Hideaki; Miyawaki, Shuichi; Tsubaki, Kazuo; Miura, Yasusada; Omine, Mitsuhiro; Kobayashi, Toshimitsu; Naoe, Tomoki; Ohshima, Toshiteru; Hirashima, Kunitake; Ohtake, Shigeki; Takahashi, Isao; Morishima, Yasuo; Naito, K; Asou, Norio; Tanimoto, Mitsune; Sakuma, Atsushi; Ohno, Ryuzo

doi:10.1016/s0145-2126(98)00082-4

Cited by 43 publications

(45 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3,[7][8][9] Recently, an independent poor prognostic significance has been detected on basis of a prospective controlled trial. 10 CML responds well to therapy with interferon-a [11][12][13][14][15][16] or a tyrosine kinase inhibitor [17][18][19][20] and can be cured by stem cell allografting. However, whereas reversal of MF was reported during tyrosine kinase inhibition or after allografting, [18][19][20][21] the few retrospective results on the effect of interferon-a on MF in CML are controversial ranging from retardation or reversal [22][23][24][25] to progression of fibrosis during therapy with this cytokine.…”

Section: Introductionmentioning

confidence: 99%

Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia

et al. 2004

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia

et al. 2004

View full text Add to dashboard Cite

“…[20][21][22][23][24] The superiority of IFN-a over hydroxyurea and busulphan made it the standard of care. [12][13][14][25][26][27] However, treatment with IFN was associated with severe side effects. 13,19,28 Allogeneic stem cell transplantation (SCT) is the only potentially curative treatment for this disease but is associated with significant morbidity and mortality (10-40%).…”

mentioning

confidence: 99%

Treatment of chronic myeloid leukemia in the imatinib era

Aziz

Iqbal

Akram

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUNDThere is paucity of data from developing countries on the efficacy and safety of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study was to document complete and partial cytogenetic responses to imatinib in all phases of CML. Secondary objectives included evaluations of complete hematologic response, safety, time to progression, and survival.METHODSTwo hundred seventy‐five patients in all phases of CML who received treatment with imatinib from January 2001 to December 2005 were included in the study. All patients had on bone marrow or BCR‐ABL positive in peripheral blood by polymerase chain reaction.RESULTSAfter a median follow‐up of 18 months, major cytogenetic responses (Ph <35%) in chronic phase (CP), accelerated phase (AP), and blastic phase (BP) were documented in 61%, 57%, and 28% of patients, respectively. A complete cytogenetic response was observed in 39.4%, 35.7%, and 14.3% of patients in CP, AP, and BP, respectively; and a complete hematologic response was observed in 90%, 86%, and 30%, respectively. The median time to progression at 18 months was 91% in CP and 68% in AP. The overall survivals in CP, AP, and BP at 18 months was 92%, 74%, and 38%, respectively.CONCLUSIONSImpressive hematologic, cytogenetic, and molecular responses to imatinib were observed, similar to the responses reported in patients from Western countries. Patients had good compliance, toxicity was limited, and overall quality of life was improved markedly. The results indicated that the biology of CML is not different in patients from developing countries. Cancer 2007 © 2007 American Cancer Society.

show abstract

“…In a single-institution experience, IFN induced CCyR in approximately one-fifth of patients, with a median time to remission of 12-27 months depending on the IFN formulation used [38]. The rate of CCyR was substantially lower in two multicenter randomized trials of IFN compared with hydroxyurea [39,40].…”

Section: Ifnmentioning

confidence: 99%

Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment‐free remission

Erba

2015

American J Hematol

View full text Add to dashboard Cite

Imatinib was the first BCR-ABL1 tyrosine kinase inhibitor (TKI) developed for the treatment of patients with chronic myeloid leukemia (CML); subsequently, the introduction of more potent BCR-ABL1 TKIs has raised expectations regarding the speed and depth of response. This review discusses how molecular monitoring is being used as an integral part of the treatment regimen to achieve improved outcomes in patients with CML. The long-term prognostic implications of achieving early molecular response to TKI therapy and the feasibility of maintaining treatment-free remission will also be discussed in light of current clinical data.

show abstract

A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia

Cited by 43 publications

References 16 publications

Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia

Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia

Treatment of chronic myeloid leukemia in the imatinib era

Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment‐free remission

Contact Info

Product

Resources

About